PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.02%
Positive revenue growth while AVGO is negative. John Neff might see a notable competitive edge here.
7.03%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
10.15%
EBIT growth below 50% of AVGO's 27.36%. Michael Burry would suspect deeper competitive or cost structure issues.
10.59%
Operating income growth under 50% of AVGO's 27.36%. Michael Burry would be concerned about deeper cost or sales issues.
2.86%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
3.62%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
3.70%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.61%
Share reduction while AVGO is at 2.68%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.80%
Reduced diluted shares while AVGO is at 5.16%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.21%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
64.21%
OCF growth above 1.5x AVGO's 37.27%. David Dodd would confirm a clear edge in underlying cash generation.
70.86%
FCF growth above 1.5x AVGO's 44.98%. David Dodd would verify if the firm’s strategic investments yield superior returns.
61.96%
10Y revenue/share CAGR under 50% of AVGO's 684.21%. Michael Burry would suspect a lasting competitive disadvantage.
48.84%
5Y revenue/share CAGR under 50% of AVGO's 421.32%. Michael Burry would suspect a significant competitive gap or product weakness.
31.55%
3Y revenue/share CAGR under 50% of AVGO's 90.38%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
375.35%
10Y OCF/share CAGR under 50% of AVGO's 1681.41%. Michael Burry would worry about a persistent underperformance in cash creation.
205.86%
Below 50% of AVGO's 607.61%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
135.70%
3Y OCF/share CAGR 1.25-1.5x AVGO's 113.80%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
222.83%
Below 50% of AVGO's 6196.48%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
140.33%
Below 50% of AVGO's 1822.58%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
113.67%
Below 50% of AVGO's 562.35%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
43.90%
Below 50% of AVGO's 2050.41%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
8.47%
Below 50% of AVGO's 617.64%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
10.29%
Below 50% of AVGO's 383.91%. Michael Burry suspects a serious short-term disadvantage in building book value.
520.27%
Dividend/share CAGR of 520.27% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
121.41%
Below 50% of AVGO's 852.32%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
81.19%
Below 50% of AVGO's 374.17%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
6.67%
AR growth well above AVGO's 11.79%. Michael Burry fears inflated revenue or higher default risk in the near future.
2.85%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
5.83%
Asset growth above 1.5x AVGO's 0.72%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
0.54%
Under 50% of AVGO's 7.39%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
24.23%
Debt growth far above AVGO's 0.03%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-0.26%
Our R&D shrinks while AVGO invests at 1.19%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
1.85%
SG&A growth well above AVGO's 1.03%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.